QUINOLINE ANTIMALARIALS - MECHANISMS OF ACTION AND RESISTANCE

Authors
Citation
M. Foley et L. Tilley, QUINOLINE ANTIMALARIALS - MECHANISMS OF ACTION AND RESISTANCE, International journal for parasitology, 27(2), 1997, pp. 231-240
Citations number
60
Categorie Soggetti
Parasitiology
ISSN journal
00207519
Volume
27
Issue
2
Year of publication
1997
Pages
231 - 240
Database
ISI
SICI code
0020-7519(1997)27:2<231:QA-MOA>2.0.ZU;2-O
Abstract
The quinoline-containing antimalarial drugs, chloroquine, quinine and mefloquine, are a vital part of our chemotherapeutic armoury against m alaria. These drugs are thought to act by interfering with the digesti on of haemoglobin in the blood stages of the malaria life cycle. Chlor oquine is a dibasic drug which diffuses down the pH gradient to accumu late about a 1000-fold in the acidic vacuole of the parasite. The high intravacuolar concentration of chloroquine is proposed to inhibit the polymerisation of haem. As a result, the haem which is released durin g haemoglobin breakdown builds up to poisonous levels, thereby killing the parasite with its own toxic waste. The more lipophilic quinolinem ethanol drugs, mefloquine and quinine, are not concentrated so extensi vely in the food vacuole and probably have alternative sites of action . The technique of photoaffinity labelling has been used to identify a series of proteins which interact specifically with mefloquine. These studies have led us to speculate that the quinolinemethanols bind to high density lipoproteins in the serum and are delivered to the erythr ocytes where they interact with an erythrocyte membrane protein, known as stomatin, and are then transferred to the intracellular parasite v ia a pathway used for the uptake of exogenous phospholipid. The final target(s) of quinine and mefloquine action are not yet fully character ised, but may include parasite proteins with apparent molecular weight s of 22 kDa and 36 kDa. As resistance to the quinoline antimalarials r ises inexorably, there is an urgent need to understand the molecular b asis for decreased drug sensitivity, A parasite-encoded homologue of P -glycoprotein has been implicated in the development of drug resistanc e, possibly by controlling the level of accumulation of the quinoline- containing drugs. As our molecular understanding of these processes in creases, it should be possible to design novel antimalarial strategies ,which circumvent the problem of drug resistance. (C) 1997 Australian Society for Parasitology. Published by Elsevier Science Ltd.